Adenovirus-Associated Hemorrhagic Cystitis Treated with Intravenous Ribavirin

摘要: Adenovirus hemorrhagic cystitis following bone marrow transplantation occurs in 2 to 16% of the patients. While usually self-limiting, this disease can cause significant morbidity and even mortality immunocompromised patient. Risk factors include graft versus host pre-transplant seropositivity adenovirus. Standard treatment disorder consists hydration, diuresis analgesics. Failure these measures leads multiple blood transfusions, severe patient possible death. When conservative therapy is unsuccessful, there no proved standard care. We recently used ribavirin, a broad-spectrum antiviral agent against adenovirus infection vitro, treat refractory after transplantation. The hematuria urinary symptomatology resolved without demonstrable side effects. present ribavirin as therapeutic alternative when for fails.